Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells

B. Brodská, P. Otevřelová, A. Holoubek,

. 2014 ; 2014 (-) : 165303.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Moreover, decrease of survivin expression level is accompanied by its delocalization from centromere-related position in mitotic cells suggesting that both antiapoptotic and cell cycle regulation roles of survivin are affected by DAC + SAHA action. Addition of subtoxic concentration of all-trans-retinoic acid (ATRA) increases the efficiency of DAC + SAHA combination on viability, apoptosis induction, and ROS generation in HL-60 cells but has no effect in CML-T1 cell line. Peripheral blood lymphocytes from healthy donors showed no damage induced by DAC + SAHA + ATRA combination. Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014093
003      
CZ-PrNML
005      
20150428115219.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2014/165303 $2 doi
035    __
$a (PubMed)25140197
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brodská, Barbora $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
245    10
$a Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells / $c B. Brodská, P. Otevřelová, A. Holoubek,
520    9_
$a While p53-dependent apoptosis is triggered by combination of methyltransferase inhibitor decitabine (DAC) and histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in leukemic cell line CML-T1, reactive oxygen species (ROS) generation as well as survivin and Bcl-2 deregulation participated in DAC + SAHA-induced apoptosis in p53-deficient HL-60 cell line. Moreover, decrease of survivin expression level is accompanied by its delocalization from centromere-related position in mitotic cells suggesting that both antiapoptotic and cell cycle regulation roles of survivin are affected by DAC + SAHA action. Addition of subtoxic concentration of all-trans-retinoic acid (ATRA) increases the efficiency of DAC + SAHA combination on viability, apoptosis induction, and ROS generation in HL-60 cells but has no effect in CML-T1 cell line. Peripheral blood lymphocytes from healthy donors showed no damage induced by DAC + SAHA + ATRA combination. Therefore, combination of ATRA with DAC and SAHA represents promising tool for therapy of leukemic disease with nonfunctional p53 signalization.
650    _2
$a protinádorové antimetabolity $x farmakologie $7 D000964
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a azacytidin $x analogy a deriváty $x toxicita $7 D001374
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a synergismus léků $7 D004357
650    _2
$a kontrolní body fáze G2 buněčného cyklu $x účinky léků $7 D059565
650    _2
$a HL-60 buňky $7 D018922
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x toxicita $7 D006877
650    _2
$a inhibitory apoptózy $x metabolismus $7 D051034
650    _2
$a lymfocyty $x cytologie $x účinky léků $x imunologie $7 D008214
650    _2
$a kontrolní body M fáze buněčného cyklu $x účinky léků $7 D059566
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a tretinoin $x farmakologie $7 D014212
650    _2
$a nádorový supresorový protein p53 $x nedostatek $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Otevřelová, Petra $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
700    1_
$a Holoubek, Aleš $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
773    0_
$w MED00180520 $t Oxidative medicine and cellular longevity $x 1942-0994 $g Roč. 2014, č. - (2014), s. 165303
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25140197 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150428115522 $b ABA008
999    __
$a ok $b bmc $g 1071674 $s 896971
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 2014 $c - $d 165303 $i 1942-0994 $m Oxidative medicine and cellular longevity $n Oxid Med Cell Longev $x MED00180520
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...